Hydrochloric Acid → HCID 135856752, Verbindung
Reaktionsgleichung
[CH2:1]([O:3][C:4]1[CH:9]=[CH:8][C:7]([S:10]([N:13]2[CH2:18][CH2:17][N:16]([CH3:19])[CH2:15][CH2:14]2)(=[O:12])=[O:11])=[CH:6][C:5]=1[C:20]1[NH:25][C:24](=[O:26])[C:23]2=[C:27]([CH3:33])[N:28]=[C:29]([CH2:30][CH2:31][CH3:32])[N:22]2[N:21]=1)[CH3:2].[ClH:34]>C(OCC)C>[ClH:34].[CH2:1]([O:3][C:4]1[CH:9]=[CH:8][C:7]([S:10]([N:13]2[CH2:14][CH2:15][N:16]([CH3:19])[CH2:17][CH2:18]2)(=[O:12])=[O:11])=[CH:6][C:5]=1[C:20]1[NH:25][C:24](=[O:26])[C:23]2=[C:27]([CH3:33])[N:28]=[C:29]([CH2:30][CH2:31][CH3:32])[N:22]2[N:21]=1)[CH3:2]Komponenten
4
Edukt 2
Produkt 1
Reagenzien, Katalysatoren, Lösungsmittel 1
Versuchsvorschrift
100 mg (0.211 mmol) of 2-[2-ethoxy-5-(4-methyl-piperazine-1-sulphonyl)-phenyl]-5-methyl-7-propyl-3H-imidazo[5,1-f][1,2,4]triazin-4-one are suspended in 5 ml of diethyl ether, admixed with 0.23 ml of a 1M solution of HCl in ether and stirred at room temperature for 15 minutes. The solvent is removed under reduced pressure. This gives 107 mg (97%) of 2-[2-ethoxy-5-(4-methyl-piperazine-1-sulphonyl)-phenyl]-5-methyl-7-propyl-3H-imidazo[5,1-f][1,2,4]triazin-4-one hydrochloride.